INTRODUCTION {#sec1-1}
============

Despite a decline in the incidence of gastric cancer (GC) in the last decades, concerns have been raised about the stable or even slightly increasing trend in young patients.\[[@ref1]\] GC occurs primarily in elderly patients with an average onset age of 60 years, and conventionally those who receive a diagnosis before the age of 40 years are distinctively defined as "young."\[[@ref2][@ref3]\] GC in young patients shares more aggressive disease characteristics including delay of diagnosis, more diffuse lesions, advanced tumor stage, poorly differentiated histology, higher noncurability rate, and has a greater likelihood of underlying hereditary genetic abnormalities.\[[@ref4][@ref5][@ref6][@ref7]\] These factors have contributed to unfavorable prognosis in young patients, although this issue remains controversial.\[[@ref8][@ref9][@ref10][@ref11]\] However, current evidence guiding the management of young patients with GC is based on data derived from all patients but may be inappropriate for some.

In addition, in many cancer types, survival is increasing at a slower rate within the young population compared with other age groups, highlighting the need for more investigation on this vulnerable group.\[[@ref12][@ref13][@ref14]\] To optimize choice of treatment strategies and maximize efficacy, it is necessary to precisely and individually estimate survival and choose corresponding treatment strategies. Nomograms have been developed to visually predict prognosis and optimize risk stratification by integrating prognostic factors into a prognosis-prediction tool.\[[@ref15][@ref16]\] To date, however, a well-constructed and externally validated nomogram for young patients with nonmetastatic GC remains missing.

Against this background, we sought to describe the clinicopathologic characteristics and develop a nomogram to predict 3- and 5-year overall survival (OS) rates based on a cohort of young patients with nonmetastatic GC from the Surveillance, Epidemiology and End Results (SEER) database. Furthermore, the nomogram was externally validated in an external patient cohort from our department.

PATIENTS AND METHODS {#sec1-2}
====================

Patient selection in the SEER database {#sec2-1}
--------------------------------------

The SEER database, released in 2018, was queried for this study. SEER, a US national population-based cancer registry, collects cancer incidence and survival data from 18 sites covering approximately 30% of the United States.\[[@ref17]\] A total of 1627 patients aged \<40 years with single primary pathologically confirmed GC between 2006 and 2015 were identified using specific site and histologic codes (site codes: C16.0--C16.6, C16.8--C16.9, histologic codes: 8010--8231, 8255--8576). Patients were excluded if they had incomplete tumor staging information (*n* = 105), distant metastasis (*n* = 525), unknown status of metastasis (*n* = 425), or unknown follow-up (*n* = 13). Finally, a total of 559 cases were designated as the training set for OS analyses.

Data retrieved from SEER database included patient demographics (sex, age at diagnosis, and race), clinicopathologic characteristics (tumor subsites, tumor size, differentiation, histology classification), surgery (surgery of primary site, number of lymph nodes (LN) examined and number of positive LN), survival time and vital status at last follow-up. Race was categorized as Asian or Pacific Islander (API) and non-API. Tumor location was classified as four subsites: cardia (C16.0); middle, including the fundus, body, or curvatures (C16.1, C16.2, C16.5, and C16.6); distal, comprising the antrum or pylorus (C16.3 and C16.4); and overlapping or not otherwise specified (C16.8 and C16.9). Histological types were classified according to Lauren\'s classification into diffuse type (histologic codes: 8020--8022, 8142, 8145 and 8490), intestinal type (8140, 8144, 8210--8211, 8260 and 8480--8481), or other.\[[@ref18][@ref19]\] Tumor size was transformed into a categorical variable based on optimal cutoff values obtained through the X-tile program. All cases were restaged according to the eighth American Joint Committee on Cancer (AJCC) TNM staging system. The end point of the study was OS which was calculated from the date of diagnosis to the date of death.

We also retrieved records of young patients with nonmetastatic GC between 2009 and 2015 from National Cancer Centre/Cancer Hospital in China. The inclusion criteria included complete demographic data, clinicopathological information, therapeutic procedure records and full follow-up results. In total, 201 patients met the inclusion criteria and were designated as the external validation set. The ethics committee of National Cancer Centre/Cancer Hospital approved this retrospective study.

Development of the nomogram {#sec2-2}
---------------------------

For nomogram construction, the SEER dataset was designated as the training set. In this cohort, survival for different variable values was compared using the log-rank test. Variables that achieved statistical significance at *P* \< 0.05 were entered into the multivariate analyses via the Cox proportional hazards regression model. Included covariates were race, tumor subsites, tumor size, depth of invasion, lymph node metastasis, number of examined LN and surgery. Based on the predictive model with the identified prognostic factors, a nomogram was constructed for predicting 3- and 5-year OS rates.

Validation of the nomogram {#sec2-3}
--------------------------

The performance of the nomogram involved discrimination and calibration in both datasets. Both discrimination and calibration were evaluated using bootstrapping with 1000 resamples.\[[@ref20][@ref21]\] Discrimination was evaluated using the *C* index. The *C* index is measured on a scale of 0.5 (random chance) to 1 (perfect discrimination). Calibration was performed by comparing the predicted survival probabilities with actual survival probabilities. External validation of the nomogram was performed using the validation set comprising the patient cohort in our department.

Statistical analysis {#sec2-4}
--------------------

The cutoff points of tumor size were explored using the X-tile program (<http://www.tissuearray.org/rimmlab/>) which identified the cutoff values with the minimum *P* values from log-rank χ^2^statistics for the variable, in terms of OS. Univariate and multivariate analyses were performed with the Cox proportional hazards model using SPSS version 22.0 (IBM). Nomogram and calibration plots were computed with the rms package in R version 3.4.4 (<http://www.r-project.org/>). Statistical significance was set as *P* \< 0.05 in a two-tailed test.

RESULTS {#sec1-3}
=======

Clinical characteristics and survival {#sec2-5}
-------------------------------------

The demographic features and clinicopathological characteristics of the training and validation sets are presented in [Table 1](#T1){ref-type="table"}. Overall, the majority of patients were non-API (83.4%), with 54.2% of the cohort male and a median age of 35 years. The most frequent tumor subsites were the distal (27.9%) and middle (27.2%) regions of the stomach. In the training dataset, the median follow-up was 21 months, and 239 (42.8%) patients died prior to completion of the present study. The 1-, 3- and 5-year OS rates were 80.5%, 54.3% and 45.9%, respectively.

###### 

Demographic and clinicopathologic characteristics of the training and validation sets

  Variables                    Training set (*n*=559)   Validation set (*n*=201)         
  ---------------------------- ------------------------ -------------------------- ----- ------
  Age (years)                                                                            
   Mean                        35                                                  35    
  Sex                                                                                    
   Male                        303                      54.2                       101   50.2
   Female                      256                      45.8                       100   49.8
  Race                                                                                   
   Non-API                     466                      83.4                             
   API                         93                       16.6                       201   100
  Size (cm)                                                                              
   Unknown                     144                      25.8                       25    12.4
   \<4.0                       194                      35.3                       101   50.3
   4.0-7.0                     144                      49.7                       62    30.8
   \>7.0                       77                       15.0                       13    6.5
  Examined LNs, No.                                                                      
   \<15                        230                      41.1                       39    19.4
   ≥16                         329                      58.9                       162   80.6
  Differentiation                                                                        
   Unknown                     45                       8.1                        5     2.5
   Well differentiated         16                       2.9                        1     0.5
   Moderately differentiated   70                       12.5                       6     3.0
   Poorly differentiated       411                      73.5                       187   93.0
   Non-differentiated          17                       8.1                        2     1.0
  Tumor subsites                                                                         
   Cardia                      138                      24.7                       10    5.0
   Middle                      152                      27.2                       61    30.3
   Distal                      156                      27.9                       107   53.3
   Overlapping/NOS             113                      20.2                       23    11.4
  Histological type                                                                      
   Diffuse                     293                      52.4                       104   51.7
   Intestinal                  243                      43.5                       70    34.9
   Other                       23                       4.1                        27    13.4
  Depth of invasion                                                                      
   T1                          108                      19.3                       59    29.4
   T2                          63                       11.3                       21    10.4
   T3                          201                      36.0                       29    14.4
   T4a                         125                      22.4                       77    38.3
   T4b                         62                       11.1                       15    7.5
  Lymph node metastasis                                                                  
   N0                          202                      36.1                       82    40.8
   N1                          143                      25.6                       30    14.9
   N2                          94                       16.8                       33    16.4
   N3a                         85                       16.8                       34    16.9
   N3b                         35                       6.3                        22    11
  Cancer stage\*                                                                         
   IA                          89                       15.9                       50    24.9
   IB                          42                       7.5                        17    8.4
   IIA                         63                       11.3                       12    6.0
   IIB                         80                       11.3                       20    10.0
   IIIA                        130                      14.3                       45    22.4
   IIIB                        102                      23.3                       46    22.9
   IIIC                        53                       9.5                        11    5.4
  Surgery                                                                                
   No surgery                  95                       17.0                       20    10.0
   Gastrectomy only            399                      71.4                       177   88.0
   Combined organs resection   65                       11.6                       4     2.0

LN: Lymph nodes, API: Asian or Pacific Islander, NOS: Not otherwise specified. \*Cancer was staged based on AJCC 8^th^ TNM staging system

Identification of cutoff points for the tumor size in the validation set {#sec2-6}
------------------------------------------------------------------------

X-tile plots were constructed and the maximum χ^2^log-rank value of 7.5478 (low vs. moderate), 5.8808 (moderate vs. high) and 24.3070 (low vs. high) (*P* \< 0.001) was produced, applying 3.9 and 7.0 cm as the optimal cutoff values to divide the cohort into low, moderate and high-risk subsets in terms of OS \[[Figure 1](#F1){ref-type="fig"}\].

![X-tile analysis of survival data from the SEER database. X-tile plot of the training set is displayed in the (a). The optimal cutoff value marked by the black circle in the Figure 1a is shown by a histogram of the entire cohort (b), and a Kaplan--Meier plot (c). *P* values were calculated using the cutoff point defined in the training set and validating it to the validation set. The figure shows the optimal cutoff points for young patients with gastric cancer (3.9 and 7.0 cm,*P*\< 0.001)](SJG-25-236-g001){#F1}

Development of the nomogram {#sec2-7}
---------------------------

Results of the univariate and multivariate regression model are listed in [Table 2](#T2){ref-type="table"}. Univariate analysis suggested that race, tumor subsites, tumor size, differentiation, depth of invasion, lymph node metastasis, number of examined LN, and surgery are associated with OS (*P* \< 0.05). Multivariable analyses continued to demonstrate that race, tumor subsites, tumor size, depth of invasion, lymph node metastasis, number of examined LN and surgery are independent risk factors for OS.

###### 

Univariate and multivariate Cox regression analysis of factors associated with OS in the training set

  Variables                    Univariate analysis    Multivariate analysis                          
  ---------------------------- ---------------------- ----------------------- ---------------------- ---------
  Age (years)                  1.017 (0.990-1.044)    0.215                                          
  Sex                          1.050 (0.814-1.355)    0.706                                          
  Race                                                                                               
   Non-API                     1 \[Ref.\]                                     1 \[Ref.\]             
   API                         1.447 (1.060-1.974)    0.020                   0.409 (0.269-0.624)    \<0.001
  Size (cm)                                                                                          
   Unknown                                                                    1 \[Ref.\]             
   \<4.0                       1 \[Ref.\]                                     0.579 (0.377-0.889)    0.012
   4.0-7.0                     2.531 (1.884-3.400)    \<0.001                 0.738 (0.492-1.109)    0.738
   \>7.0                       3.972 (2.779-5.677)    \<0.001                 1.294 (0.827-2.025)    0.258
  Differentiation                                                                                    
   Unknown                     1 \[Ref.\]                                     1 \[Ref.\]             
   Well differentiated         0.404 (0.139-1.172)    0.095                   0.589 (0.195-1.774)    0.347
   Moderately differentiated   0.482 (0.267-0.871)    0.016                   0.578 (0.309-1.081)    0.086
   Poorly differentiated       0.844 (0.542-1.313)    0.451                   0.895 (0.562-1.425)    0.639
   Undifferentiated            0.655 (0.266-1.617)    0.359                   0.511 (0.200-1.308)    0.162
  Tumor subsites                                                                                     
   Overlapping/NOS             1 \[Ref.\]                                     1 \[Ref.\]             
   Cardia                      0.575 (0.406-0.816)    0.002                   0.916 (0.621-1.352)    0.659
   Middle                      0.482 (0.335-0.693)    \<0.001                 0.751 (0.511-1.105)    0.144
   Distal                      0.484 (0.341-0.687)    \<0.001                 0.648 (0.443-0.950)    0.026
  Histological type                                                                                  
   Other                       1 \[Ref.\]                                                            
   Diffuse                     1.340 (0.657-2.735)    0.421                                          
   Intestinal                  1.079 (0.524-2.220)    0.837                                          
  Depth of invasion                                                                                  
   T1                          1 \[Ref.\]                                     1 \[Ref.\]             
   T2                          2.421 (1.204-4.869)    0.013                   3.365 (1.641-6.903)    0.001
   T3                          4.311 (2.456-7.568)    \<0.001                 4.407 (2.344-8.285)    \<0.001
   T4a                         6.998 (3.949-12.402)   \<0.001                 6.984 (3.653-13.350)   \<0.001
   T4b                         8.264 (4.466-15.292)   \<0.001                 8.142 (4.114-16.112)   \<0.001
  Lymph node metastasis                                                                              
   N0                          1 \[Ref.\]                                     1 \[Ref.\]             
   N1                          2.152 (1.514-3.060)    \<0.001                 1.205 (0.822-1.767)    0.339
   N2                          1.862 (1.249-2.776)    \<0.001                 1.270 (0.808-1.998)    0.300
   N3a                         2.123 (1.434-3.143)    \<0.001                 1.653 (1.052-2.597)    0.029
   N3b                         3.589 (2.202-5.851)    \<0.001                 2.384 (1.340-4.241)    0.003
  Examined LNs, No                                                                                   
   \<15                        1 \[Ref.\]                                     1 \[Ref.\]             
   ≥16                         0.622 (0.480-0.805)    \<0.001                 0.656 (0.475-0.907)    0.011
  Surgery                                                                                            
   No surgery                  1 \[Ref.\]                                     1 \[Ref.\]             
   Gastrectomy only            0.296 (0.219-0.401)    \<0.001                 0.339 (0.222-0.518)    \<0.001
   Combined organs resection   0.311 (0.198-0.488)    \<0.001                 0.211 (0.119-0.375)    \<0.001

OS: Overall survival, HR: Hazard ratio, CI: Confidence interval, API: Asian or Pacific Islander, NOS: Not otherwise specified, LNs: Lymph nodes

A nomogram predicting 3- and 5-year OS rates was established from selected covariates with hazard ratios from the Cox multivariate regression model in the training set \[[Figure 2](#F2){ref-type="fig"}\]. Each subtype within these covariates was assigned a point on the point scale. By adding the total points together and locating it on the bottom scale, we were able to calculate the probability of 3- and 5-year OS.

![A nomogram to predict 3- and 5-year overall survival rates of young patients with nonmetastatic gastric cancer](SJG-25-236-g002){#F2}

Discrimination and calibration of the nomogram {#sec2-8}
----------------------------------------------

We compared the discrimination of the nomogram with that of the eighth AJCC TNM classification system in the training set. The nomogram discrimination was 0.762 (95% CI = 0.733--0.791), which was superior to that of the traditional AJCC TNM classification (0.635, 95% CI = 0.597--0.673, *P* \< 0.001). Discrimination was also enhanced compared with the eighth AJCC TNM staging with regard to the validation set (*C* index = 0.805, 95% CI = 0.705--0.855 vs. 0.712 and 0.667--0.756, P= 0.176), but the difference was insignificant. The prognostic model for OS that was derived from the Western population also showed optimal discrimination in Asian population.

Calibration plots were generated to validate agreement between the actual survival rates and predicted survival rates by the nomogram \[[Figure 3](#F3){ref-type="fig"}\]. The x axis is the survival rate predicted by the nomogram, whereas the y axis is the actual survival rate obtained using the Kaplan--Meier method. The dashed line represents the ideal reference line where predicted survival corresponded with the actual survival. The calibration curve presented a good agreement between the nomogram prediction and actual observation for 3- and 5-year OS rates in the training set and validation set.

![Calibration plots of the nomogram in the training set (a and c) and validation set (b and d). (a and b) Three-year overall survival and (c and d) 5-year overall survival. The *x*-axis represents the nomogram-predicted survival, and the *y*-axis represents actual survival and 95% CI measured by Kaplan--Meier analysis. The line represents the ideal reference line where predicted survival corresponds with the actual survival](SJG-25-236-g003){#F3}

DISCUSSION {#sec1-4}
==========

In this study, we identified race, tumor subsites, tumor size, depth of invasion, lymph node metastasis, number of examined LN and surgery as independent prognostic factors for OS through univariate analysis and multivariate analysis. We further integrated these factors into a nomogram to predict 3- and 5-year OS rates and validated the model in an external patient cohort. The model is more predictive than the eighth AJCC TNM classification, with higher *C* indexes and good calibration in both cohorts.

Reports about the prognosis of young patients with GC have been controversial around the world. Young patients have a greater likelihood of presenting without alarm symptoms, diffuse and signet-ring histology, more advanced tumor stage, and higher noncurability rate, suggesting that it should be treated as a separate entity.\[[@ref2][@ref22][@ref23]\] However, such conclusions are limited by a retrospective design, small sample size, univariate analysis, significant confounding effects and limited data from the past 10 years in the existing studies. De *et al*. examined young adults with gastric adenocarcinoma from the National Cancer Database to describe demographics and to develop a nomogram to predict survival.\[[@ref24]\] However, this nomogram was not externally validated in an independent center. To address these flaws, we developed our nomogram using records from a US-population database in the last 10 years and externally validated the nomogram in an independent cohort to ensure generality.

Several clinicopathological characteristics and treatment information were identified as independent covariates associated with OS in young patients with nonmetastatic GC, including race, tumor subsites, tumor size, depth of invasion, lymph node metastasis, number of examined LN and surgery. In comparison to previous nomograms that targeted the entire population, tumor size was selected as an independent prognostic factor in our study. We categorized tumor size using optimal cutoff values for the sake of clinical convenience. Although continuous variables are more information-preserving than categorical variables, adding the points from each variable together and obtaining the probability of survival on the total points row can be ambiguous and cumbersome. We also uncovered an interesting survival advantage of API over other race ethnicities in the Western population-derived training cohort, which has been confirmed by previous studies.\[[@ref25][@ref26][@ref27][@ref28]\] An investigation based on SEER database suggested that the GC survival gap could be partially attributed to a higher proportion of cardia tumors among the Western population, as also suggested in the present study.\[[@ref29]\] Risk factor prevalence in different populations may account for this variation. A major risk factor for noncardia GC in Eastern countries is *Helicobacter pylori* infection, whereas obesity and gastroesophageal reflux in Western countries are associated with cardia cancer.\[[@ref30][@ref31][@ref32][@ref33]\] Regular screening and earlier diagnosis in Asian-Americans also partially accounted for this survival gap. In line with their stronger awareness of GC screening, their disease stage at diagnosis was earlier than that of non-Hispanic whites.\[[@ref29]\] However, even after adjustment for tumor subsites, disease stage and other covariates, survival advantage in Asians remained significant. Further research is needed to investigate this phenomenon.

Multiple GC survival nomograms have been built to predict survival for distinct populations. Kattan *et al*. constructed a nomogram in 2003 using Western patient data to predict GC survival after R0 resection.\[[@ref34]\] We believe treatment modalities were largely different in a span of more than 10 years, so were practice patterns of physicians and surgeons who treated these patients. Wang *et al*. developed a nomogram for patients with insufficient LN retrieval.\[[@ref35]\] However, radical surgery with extended lymphadenectomy is the standard surgical practice in most high-volume centers in China. Dikken *et al*. developed a nomogram to predict conditional probability of survival after curative gastrectomy with extended lymphadenectomy.\[[@ref36]\] There were another three externally validated nomograms built from eastern patient dataset by Asian researchers.\[[@ref37][@ref38][@ref39][@ref40]\] It is imperative to note that younger patients were unrepresented in previous studies, suggested by their small percentage in the total study population (ranging from 7.3% to 9.5%). GC is less likely to affect younger people, with less than 5% of all new cases diagnosed in patients \<40 years of age.\[[@ref41]\] Due to various inherent biases we mentioned above, we decided not to validate previous nomograms in our cohort but rather to establish a new one and validate it in our exclusively Eastern younger patient cohort. Both the original and validation dataset were limited to subjects diagnosed between 2006 and 2015 in order to represent the contemporary practice patterns of GC management. It was a pity that the *C* index of our nomogram (0.762) was slightly inferior to that of previous ones (ranging from 0.742 to 0.87), which did not actually indicate inferior predictive value or clinical usefulness. The true measure of applicability is the successful validation of the nomogram in a cohort with similar characteristics, demographics and disease outcomes, which we have done in the current study. Although the *C* index of previous nomograms exceeded that of ours, this might just indicate features of the data from which they were derived.\[[@ref42]\] The true comparison between different nomograms is applying them separately in the same population and comparing their *C* index.

It is uncommon to observe that the discrimination of the nomogram in training set is slightly inferior to the validation set. Usually, the discriminative performance of a nomogram in the original dataset is expected to be better than the validation dataset. More favorable prognosis and subsequent higher proportion of censored data in the validation dataset may account for its higher *C* index. First, lymphadenectomy in training set is less extensive than the validation set. The percentage of number of examined LN ≥16 (a threshold required by Japanese GC treatment guideline to ensure accurate staging\[[@ref43]\]) is 58.9% and 80.6% in training set and validation set, respectively. More extensive lymphadenectomy improved the prognosis of the validation set and thus increased the percentage of censoring events. Moreover, a homogeneous racial break-up of Asian ethnicity in the training set is an independent factor for favorable survival, as confirmed by a previous and the present study.\[[@ref29]\] With the most commonly applied methods of *C* index calculation, higher percentage of censored data will overestimate nomogram *C* index, whereas more death events will decrease the *C* index.\[[@ref44]\]

We further compared the discrimination of this nomogram with that of the eighth AJCC TNM staging system. Discriminative superiority of the nomogram over the traditional TNM classification had been suggested in both cohorts, but statistical significance was not reached in the validation set (*P* = 0.176). We believe that small sample size of the validation set (*n* = 201) may contribute to this insignificance. The calibration plots of the training set and validation set illustrated good agreement between nomogram prediction and actual observation, suggesting that predictive performance of the nomogram was good.

There are several advantages of using this nomogram in this study. First, survival could be visually and individually estimated by both clinicians and patients through this scoring system. Second, identifying subsets of patients at high risk of unfavorable prognosis might have an impact on the choice of tailored treatment option. Third, because our nomogram is a well-predicting tool for 3- and 5-year OS rates, a more reasonable follow-up schedule could be developed through this nomogram.

There are some limitations to this study. First, we excluded patients with incomplete information, which may cause a selection bias. Second, SEER database is population-based but not hospital-based, because information for all cancer cases are reported from local cancer registries. As such, parameters including *H. pylori* status, types of systemic therapy received, measurement of response to treatment and molecular data could not be analyzed. Third, discrimination of the nomogram was overestimated in the validation set due to a higher proportion of censored data. Finally, due to the retrospective design of our study, intrinsic biases of such a study format are hard to eliminate. Clearly, our results should be further validated in prospective multicenter studies before being applied in the clinical setting.

CONCLUSION {#sec1-5}
==========

We established a nomogram for predicting 3- and 5-year OS rates for young patients with nonmetastatic GC using the US population-based database and validated in an independent patient cohort from our department. This nomogram could estimate survival precisely and individually and identify patients at high risk of unfavorable survival for whom individualized treatment strategy is required.
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